ATE323886T1 - Verfahren zur diagnose der alzheimerschen krankheit - Google Patents

Verfahren zur diagnose der alzheimerschen krankheit

Info

Publication number
ATE323886T1
ATE323886T1 AT02705902T AT02705902T ATE323886T1 AT E323886 T1 ATE323886 T1 AT E323886T1 AT 02705902 T AT02705902 T AT 02705902T AT 02705902 T AT02705902 T AT 02705902T AT E323886 T1 ATE323886 T1 AT E323886T1
Authority
AT
Austria
Prior art keywords
disease
diagnosing alzheimer
glycoproteins
dementia
diagnosis
Prior art date
Application number
AT02705902T
Other languages
English (en)
Inventor
David Henry Small
Lisa Fodero
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of ATE323886T1 publication Critical patent/ATE323886T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT02705902T 2001-01-23 2002-01-23 Verfahren zur diagnose der alzheimerschen krankheit ATE323886T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26384101P 2001-01-23 2001-01-23

Publications (1)

Publication Number Publication Date
ATE323886T1 true ATE323886T1 (de) 2006-05-15

Family

ID=23003453

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02705902T ATE323886T1 (de) 2001-01-23 2002-01-23 Verfahren zur diagnose der alzheimerschen krankheit

Country Status (6)

Country Link
US (1) US20020150878A1 (de)
EP (1) EP1356299B1 (de)
AT (1) ATE323886T1 (de)
CA (1) CA2442708A1 (de)
DE (1) DE60210741D1 (de)
WO (1) WO2002059619A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020033126A (ko) * 2002-03-08 2002-05-04 김용선 병원성 프리온 단백의 n말단의 비효소적 당화반응 최종산물의 검출에 의한 프리온 질환의 진단
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
ES2889914B2 (es) * 2020-07-01 2022-07-21 Univ Miguel Hernandez De Elche PATRON DE GLICOSILACION DE sAPPalfa Y/O sAPPbeta COMO BIOMARCADOR DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER, METODO Y KIT BASADOS EN EL MISMO
WO2022042873A1 (en) 2020-08-27 2022-03-03 Immunologik Gmbh Pharmaceutically acceptable lectins derived from plants, fungi and bacteria for the treatment of sars-cov-2 infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1313496C (en) * 1988-04-29 1993-02-09 James Wilson Dennis Diagnostic method to screen tumors
AUPO943297A0 (en) * 1997-09-24 1997-10-16 University Of Melbourne, The Diagnostic test for alzheimer's disease
AU2001259046A1 (en) * 2000-04-07 2001-10-23 Monash University Diagnostic test for alzheimer's disease

Also Published As

Publication number Publication date
WO2002059619A3 (en) 2002-10-17
EP1356299A2 (de) 2003-10-29
US20020150878A1 (en) 2002-10-17
DE60210741D1 (de) 2006-05-24
WO2002059619A2 (en) 2002-08-01
CA2442708A1 (en) 2002-08-01
EP1356299B1 (de) 2006-04-19

Similar Documents

Publication Publication Date Title
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
MA29528B1 (fr) Agents de fixation
IN2014DN05011A (de)
ATE404118T1 (de) System für kontinuierliche leistungstests
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
CA2420186A1 (en) Methods for diagnosing a neurodegenerative condition
WO2002010725A3 (en) Method for non-invasively determining the concentration of an analyte by compensating for the effect of tissue hydration
DE60232522D1 (de) Verfahren zur vorhersage der behandlungsresultate
WO2006036601A3 (en) Process control monitors for the fabrication interferometric modulators
WO2000072015A3 (en) Diagnostics and therapeutics for cardiovascular disorders
CA2374521A1 (en) Test question response verification system
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
ATE324624T1 (de) Verfahren zur prozessgesteuerten und kundenindividuellen herstellung eines gegenstandes
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
DE60210741D1 (de) Verfahren zur diagnose der alzheimerschen krankheit
HUP0003684A2 (hu) Alzheimer-kór diagnosztizálására szolgáló vizsgálat
FI20031370A0 (fi) Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
AU2002238766A1 (en) Diagnostic screens for alzheimer's disease
ATE391954T1 (de) Verfahren zur steuerung eines ressourcenzugriffs eines prozesses durch einen elternprozess
DE60137513D1 (de) Methode zur Diagnose von oder zur Bestimmung des Risikos für Psychose beinhaltend die Bestimmung einer heterozygoten Mutation der Methylentetrahydrolfolatreduktase (MTHFR)
WO2001085980A3 (en) Enzymatic assays for screening anti-cancer agents
DE602004030819D1 (de) Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs
WO2004035597A3 (en) Methods of assessing the risk of reproductive failure by measuring telomere length

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties